Misoprostol vaginal insert for successful labor induction: a randomized controlled trial.

Area of Science:

• Obstetrics and Gynecology
• Reproductive Medicine
• Clinical Pharmacology

Background:

• Labor induction is a common obstetric procedure.
• Misoprostol vaginal insert (MVI) is used for labor induction.
• Optimizing MVI dosage is crucial for balancing efficacy and safety.

Purpose of the Study:

• To compare the efficacy and safety of three doses of misoprostol vaginal insert (MVI) for labor induction.
• Primary outcome: proportion of vaginal deliveries within 24 hours.
• Secondary outcomes: time to vaginal delivery, cesarean delivery rates, and adverse events.

Main Methods:

• Randomized controlled trial involving 374 women with unfavorable Bishop scores.
• Women received MVI 100, 150, or 200 micrograms.
• MVI was removed upon active labor onset or adverse events.
• Vaginal delivery within 24 hours was the primary endpoint.

Main Results:

• MVI 200 did not significantly improve the proportion of vaginal deliveries within 24 hours compared to MVI 100 (24% vs. 36.3%).
• MVI 200 significantly reduced median time to vaginal delivery (1,181 vs. 1,744 minutes) and need for oxytocin.
• Cesarean delivery rates were similar between MVI 200 and MVI 100 groups (22.9% vs. 31.4%).
• MVI 200 was associated with a higher rate of tachysystole (41.2% vs. 19.5%).

Conclusions:

• MVI 200 accelerates labor induction time but does not increase the likelihood of vaginal delivery within 24 hours compared to MVI 100.
• The higher dose (MVI 200) is associated with increased uterine tachysystole.
• Dosage optimization of MVI for labor induction requires careful consideration of efficacy and safety trade-offs.